EQ
$2.15
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.
Recent News
Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start
Executives from Equillium (NASDAQ:EQ) outlined the scientific rationale and near-term development plans for its lead program, EQ504, during a recent fireside chat focused on immunology and inflammatory bowel disease (IBD). Positioning EQ504 in ulcerative colitis Company representatives described ul
Trending tickers: Intel, Tilray, monday.com, Equillium and AMC
The latest investor updates on stocks that are trending on Tuesday
BC-Most Active Stocks
Gibo Holdings Ltd. 239,477,124 0.049
Spotlight On 3 Promising Penny Stocks With Over $20M Market Cap
As the U.S. markets react to recent economic uncertainties, including weak job reports and tariff concerns, investors are reassessing their strategies amid fluctuating indices. In this context, penny stocks—often perceived as remnants of a bygone era—continue to capture attention for their potential value and growth opportunities. Despite their small size or relative newness, these stocks can offer intriguing prospects when backed by solid financials.
Promising Penny Stocks To Consider In April 2025
Amid ongoing tariff uncertainties and volatile trading, the U.S. stock market is experiencing significant fluctuations, with major indices like the Dow Jones Industrial Average and S&P 500 facing substantial declines. In such a turbulent landscape, investors may find opportunities in penny stocks—an investment category that, despite its outdated name, continues to offer potential value. By focusing on companies with robust financials and clear growth trajectories, investors might uncover...